Accounting for nearly 4 billion prescriptions, generic and biosimilar medicines saved the U.S. $338 billion in 2020 alone and almost $2.4 trillion over the last decade. As more biosimilars have come to market over the last few years, the U.S. has seen $8 billion in savings in 2020. Generics account for 90% of prescriptions dispensed in the U.S., but only 18.1% of the spending and 93% of all generic prescriptions are filled for less than $20.
Viatris Support for Greater Access in Healthier Markets
At Viatris, we are committed to making medicines more accessible by increasing competition and finding policy solutions that ensure benefits of competition reach patients. We recognize that the price of medicines can present an access challenge for patients, particularly when health system policies do not adequately support the equitable provision of health services. We believe that the value created by universal access to appropriate, high-quality medicines, particularly in the off-patent sector, is greater than the savings achieved by cuts to health and medicines budgets.